Updated on 12 August 2016
The GPEx technology platform creates stable, high-yielding mammalian cell lines for even the most difficult to express proteins
Singapore: Catalent Pharma Solutions, and Zumutor Biologics Inc., has announced a successful research study, combining Catalent's proprietary GPEx technology and Zumutor's fucose knockout platform, to create new and more efficacious antibodies.
Headquartered in Somerset, N.J, USA, Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products.
Zumutor Biologics Inc is a pre-clinical stage biologics discovery and development company, headquartered in Woburn, MA with Research & Development facility in Bangalore, India.
The GPEx technology platform creates stable, high-yielding mammalian cell lines for even the most difficult to express proteins. The advantages of applying GPEx technology span from early feasibility studies and clinical manufacturing, to commercial scale production.
Working in partnership, Catalent and Zumutor have created a fucose knockout GPEx cell line expressing high levels of an anti-HER2 antibody. The resulting modification completely removes fucose from the antibody, resulting in greatly enhanced Antibody Dependent Cellular Cytotoxicity (ADCC) without impacting production levels. The study was conducted in Zumutor's research and development facility in Asia.